 |
|
|
| |
Dolutegravir versus efavirenz-400 as first-line ART in
Cameroon: week 192 data of NAMSAL trial
|
| |
| |
AIDS 2022 July 29- Aug 1 Montreal
Mireille Mpoudi-Etame
Authors
M. Mpoudi-Etame * (1), T. Tovar Sanchez (2), P. Omgba Bassega (3), J. Olinga (4), R. Pelloquin (2), M. Foalem (4), C. Njonkep (4), E. Mimbe (4), M. Varloteaux (4), M. Tongo (5), N. Lamare (5), M. Peeters (2), J. Reynes (6,2), E. Delaporte (6,2), S. Koulla-Shiro (4), C. Kouanfack (7,8,4), NAMSAL ANRS 12313 study group
Institutions
(1) Military Hospital of Yaounde, Yaounde, Cameroon, (2) TransVIHMI, University of Montpellier-IRD-INSERM, Montpellier, France, (3) District of the Cite Verte Hospital, Yaounde, Cameroon, (4) Cameroon ANRS-site, Yaounde, Cameroon, (5) CREMER, Yaounde, Cameroon, (6) Montpellier University Hospital Center, Montpellier, France, (7) Faculty of Medicine and Pharmaceutical Sciences University of Dschang, Dschang, Cameroon, (8) Yaounde Central Hospital, Yaounde, Cameroon
|
| |
|
|
|
|
|
